There is controversy about the development of bronchodilator subsensitivity after regular administration of long-acting ␤ 2 -agonists. Objectives: The purpose of the study was to evaluate whether regular treatment with formoterol affects the bronchodilator response to repeated puffs of albuterol, and also to assess the effects of acute administration of a bolus dose of IV or inhaled corticosteroid. 
S
almeterol and formoterol are long-acting ␤ 2 -agonists that are recommended for use as additional therapy to inhaled corticosteroids. 1 There is much debate about the regular use of these drugs, particularly in regard to the development of tolerance to their bronchodilator and bronchoprotective effects. 2, 3 We have previously shown that 36 h after stopping regular treatment with twice daily salmeterol there is persistent bronchodilator subsensitivity to repeated puffs of albuterol along with downregulation of lymphocyte ␤ 2 -adrenoceptors. 4 In another study with a similar design, there was no bronchodilator subsensitivity to albuterol 36 h after stopping regular treatment with twice daily formoterol. 5 There is, however, evidence of persistent bronchodilator subsensitivity to repeated puffs of formoterol 24 h after stopping regular treatment with twice daily formoterol. 6 There was criticism of the latter study because in real life clinical practice inhaled formoterol would not normally be used as repeated puffs for acute relief therapy.
The objectives of the present study were twofold. First, we wanted to assess whether bronchodilator subsensitivity to repeated puffs of albuterol occurs after regular treatment with formoterol 24 h after stopping treatment. Second, we wanted to evaluate the effect of acute administration of an IV bolus or inhaled corticosteroids on the albuterol response. We have previously shown that acute administration of a bolus dose of IV hydrocortisone, 200 mg, along with oral prednisolone, 50 mg, rapidly reversed bronchodilator subsensitivity to repeated puffs of inhaled formoterol. 7 In the present study, we have investigated the acute effects of a lower dose of systemic corticosteroid (IV hydrocortisone, 200 mg, alone) as well as a high dose of inhaled steroid (budesonide, 1.6 mg, via Turbuhaler; Astra Pharmaceuticals; Kings Langley, UK).
Materials and Methods

Patients
Twelve patients with stable, moderate to severe persistent asthma (7 women and 5 men; mean Ϯ SD age, 43 Ϯ 15 years; all taking inhaled corticosteroids) were recruited to take part in a randomized, placebo-controlled, double-blind, crossover study (Table 1 ). All were using inhaled short-acting ␤ 2 -agonists (less than two puffs per day) for symptomatic relief purposes. Two subjects were taking inhaled salmeterol and one subject was taking inhaled formoterol twice daily. Three subjects were also taking oral theophylline twice daily. The subjects had stable asthma according to the American Thoracic Society criteria 8 for at least 3 months before randomization, and no one had received oral steroids or antibiotics during this time. All subjects were nonsmokers and had demonstrated Ն 15% reversibility in FEV 1 or forced expiratory flow rate between 25% and 75% of vital capacity (FEF 25-75% ; mid-expiratory flow) to albuterol, 400 g, at recruitment. All subjects gave written informed consent before being randomized in the study, which was approved by the Tayside committee on medical research ethics.
On completion of the study, we also performed a post hoc genotype analysis of our study patients for ␤ 2 -adrenoceptor polymorphisms. All patients who were homozygous for glutamic acid (Glu)-27 were also homozygous for glycine (Gly)-16, which is a well-known linkage disequilibrium.
Protocol
A randomized, double-blind, double-dummy, crossover design was used. After an initial 1-week run-in period, subjects were randomized to receive four consecutive 2-week randomized treatment blocks with either inhaled placebo bid (in one limb) or inhaled formoterol 24 g bid (in the three other limbs). Formoterol was delivered by dry powder Turbuhaler, 12 g metered dose per actuation, 9 g delivered dose (formoterol fumarate, Oxis Turbuhaler). Placebo was also delivered using Turbuhaler. The medication was taken between 7:00 pm and 9:00 pm for the evening dose and between 7:00 am and 9:00 am for the morning dose. The last dose of each treatment was taken in the morning 24 h before each laboratory visit.
From the start of the run-in period until the end of the study, all ␤ 2 -agonist therapy was stopped and was substituted with inhaled ipratropium bromide (Atrovent Forte; Boehringer Ingelheim; Bracknell, UK) to be used as two puffs (80 g) for symptomatic rescue relief. The subjects continued to use their inhaled corticosteroids unchanged throughout the study apart from stopping them for 24 h before each study visit (ie, the last *FP ϭ fluticasone propionate; BUD ϭ budesonide; BDP ϭ beclomethasone dipropionate; M ϭ male; F ϭ female. †Codon 16: GLY ϭ homozygous Gly16/Gly16, HET ϭ heterozygous Gly16/Arg16, ARG ϭ homozygous Arg16/Arg16. ‡Codon 27: GLU ϭ homozygous Glu27/Glu27, HET ϭ heterozygous Glu27/Gln27, GLN ϭ homozygous Gln27/Gln27. dose of the study inhaler was taken with the last dose of inhaled corticosteroid). Similarly, the oral theophylline was omitted for 48 h before each study visit.
Albuterol Dose-Response Curve
Subjects attended the laboratory at 7:30 am, approximately 24 h after the last dose of each of the four treatment periods, having withheld their reliever inhaler (ipratropium) for at least 12 h. An IV cannula was inserted and kept patent with a bolus of heparinized saline solution. After at least 30 min of supine rest, blood was withdrawn for 8:00 am plasma cortisol after removing the cannula dead space of 1 mL, which was discarded.
The subjects then received from a second blinded investigator one of the following: (1) IV saline solution and inhaled placebo (after placebo pretreatment limb); (2) IV saline solution and inhaled placebo (after formoterol pretreatment); (3) IV hydrocortisone 200 mg (Solu-cortef, hydrocortisone sodium succinate; Pharmacia and Upjohn Ltd; Knowlhill, UK) and inhaled placebo (after formoterol pretreatment); or (4) IV saline solution and inhaled budesonide 1.6 mg Turbuhaler (after formoterol pretreatment). Thus, the following treatment combinations were administered: (1) placebo alone, (2) formoterol alone, (3) formoterol and hydrocortisone, and (4) formoterol and budesonide.
Plasma cortisol was collected at 8:00 am before inhalation and injection, and again at 9:00 am, 10:00 am, 11:00 am, and 12:00 noon. At 2 h after placebo or steroid administration, 40 mL of blood was withdrawn for lymphocyte ␤2-adrenoceptor analysis. A dose-response curve (DRC) to inhaled albuterol (Ventolin Accuhaler, albuterol sulfate, 200 g per actuation; Allen and Hanburys; Uxbridge, UK) was then constructed, using consecutive doses of 200 g, 200 g, 400 g, and 800 g albuterol (ie, cumulative doubling doses of 200 g, 400 g, 800 g, and 1,600 g, respectively). The doses were separated by 20-min intervals with measurements made over an 80-min period from baseline. Spirometry was performed before the first dose at baseline and 15 min after each dose increment and before the next dose of albuterol.
Domiciliary Peak Flow
The patients were instructed to record their morning and evening peak expiratory flow rate using a peak flowmeter (Vitalograph Ltd; Buckingham, UK) immediately before taking their study medication. The subjects took three readings and recorded the highest reading in the diary card.
Spirometry
Spirometry was performed according to American Thoracic Society criteria 9 using a compact spirometer (Vitalograph Ltd) with a pneumotachograph head and pressure transducer and on-line computer-assisted determination of FEV 1 and FEF 25-75% , using best test values.
Lymphocyte ␤ 2 -Adrenoceptor Binding Variables
Lymphocyte ␤ 2 -adrenoceptor binding variables were measured as previously described, using (Ϫ) 125 I-iodocyanopindolol. 10 Assessable data for lymphocyte ␤ 2 -adrenoceptor binding density (Bmax) and lymphocyte ␤ 2 -adrenoceptor binding affinity (dissociation constant; Kd) were only available in 9 of 12 patients for all four treatments because of a malfunction in the binding assay.
Plasma Cortisol Assay
The assays were performed in duplicate using a commercial radioimmunoassay kit (Immunodiagnostic Systems Ltd; UK), which has no cross-reactivity with budesonide, but could evidently not be used with hydrocortisone. The coefficients of variation for analytical imprecision for intra-assay and inter-assay were 7.1% and 7.2%, respectively.
Identification of ␤ 2 -Adrenoceptor Polymorphisms
␤ 2 -Adrenoceptor polymorphisms were identified as previously described. 11 In brief, genomic DNA was extracted from whole blood, and a 234-base pair fragment generated by polymerase chain reaction spanned the regions of interest. Genotype was determined by allele-specific oligonucleotide hybridization using probes homologous for the arginine (Arg)-16, glycine (Gly)-16, glutamine (Gln)-27, or glutamic acid (Glu)-27 forms of the receptor.
Statistical Analysis
The study was powered at the 80% level with 12 subjects to detect a 20% difference in the primary end point as ⌬FEV 1 response (area under curve between 20 and 80 min [AUC]) between placebo and active treatments. All DRC variables were analyzed as change in response from baseline. Comparisons for ⌬ responses from the DRC were made as AUC and as peak response. The lymphocyte ␤ 2 -adrenoceptor binding parameters were logarithmically transformed prior to analysis. Comparisons were made by multivariate analysis of variance, using subject, study treatment, albuterol dose, and period as factors for the analysis. This was followed by applying Bonferroni multiplerange testing (set at 95% confidence interval [CI]) to obviate multiple pairwise comparisons. The domiciliary morning and evening peak flow data were calculated as the mean of 7 days prior to the last dose of each treatment period. Data analysis was performed using a Statgraphics statistical analysis software package (STSC Software Publishing Group; Rockville, MD). The genotype data were not subjected to statistical analysis because of the small number of subjects within a given genotype for each codon.
Results
Thirteen subjects were recruited in total; 1 subject dropped out because of an exacerbation of asthma during the third formoterol limb (the last limb of the trial) caused by a chest infection. The data for this patient were excluded from the analysis, and one more subject was randomized to completion. All of these 12 subjects completed the study, and no other adverse events were reported. Treatment with formoterol produced significant improvements in morning (p ϭ 0.004) and evening (p ϭ 0.0004) domiciliary peak flow recordings as compared with placebo during all three active treatment limbs (Fig 1) .
There were no significant (p ϭ 0.3) differences in mean values for baseline FEV 1 (ie, before the DRC) between the four treatment periods (Table 2) . For the primary end point (⌬FEV 1 AUC), treatment with formoterol produced significant (p ϭ 0.01) bronchodilator subsensitivity compared with placebo for all measured variables, as evidenced by a rightward shift in the albuterol DRC (Fig 2 and There was partial reversal of the subsensitivity when formoterol was given in conjunction with inhaled or IV steroid in that the responses were not significant compared with placebo pretreatment, but at the same time were also not significant compared with pretreatment with formoterol alone. Mean values for peak delta response and AUC showed a similar trend in this respect for both FEV 1 and FEF 25-75% (Fig 2 and Table 3 ).
Individual data comparing the albuterol response between placebo and formoterol alone showed that for the ⌬FEV 1 (AUC) response in 8 of 12 subjects had Ͼ 20% attenuation, whereas for ⌬FEF 25-75% (AUC), 9 of 12 subjects had Ͼ 20% attenuation. Concerning patients who had the Gly-16 allele (ie, homozygous or heterozygous at codon 16), there were 2 of 11 who did not show subsensitivity for ⌬FEV 1 response and 1 of 11 did not show subsensitivity for ⌬FEF 25-75% response.
The 8:00 am plasma cortisol (before steroid administration) was not significantly different (p ϭ 0.8) among the three treatments (ie, placebo vs formoterol vs formoterol ϩ budesonide; Table 4 ). The 4-h plasma cortisol profile (8:00 am to 12:00 noon) showed significant (p ϭ 0.003) suppression after budesonide administration compared to placebo ( Table 4 ). The plasma cortisol profile after hydrocortisone could not be described as being caused by lack of separation between endogenous and exogenous glucocorticoids.
Discussion
Our results showed that regular twice-daily formoterol produced subsensitivity of the bronchodilator response to repeated puffs of albuterol for effects on both FEV 1 and FEF 25-75% response (as AUC). We found that an approximately eightfold higher dose of albuterol would be required to elicit the 12 There is, however, controversy about the development of bronchodilator desensitization with longacting ␤ 2 -agonists. Ullman et al, 13 Wilding et al, 14 and Nelson et al 15 with salmeterol, and Arvidsson et al 16 with formoterol reported that bronchodilator subsensitivity to albuterol did not occur. In all four of these studies, the baseline spirometry (before albuterol) was performed within 12 h of dosing with active treatment, and consequently, values were higher as compared to placebo, which would result in confounding of the subsequent albuterol response. Also, ␤ 2 -agonist rescue medication was permitted instead of ipratropium (except for Nelson et al 15 ) , and there was no ␤ 2 -agonist washout period before the study. In our study, the baseline spirometry during active treatments was performed at 24 h and was not statistically different from placebo, which may explain why it was possible to demonstrate a rightward shift in albuterol response. Furthermore, the patients in our study had more severe asthma, and hence the ceiling of the FEV 1 DRC was probably not attained. It is important to point out that we decided before the study to analyze the albuterol FEV 1 response as change from baseline in keeping with analysis of DRCs from all of our previous studies. 4 -7,12,17 Inasmuch as the ⌬FEV 1 response was used to power the study, we therefore feel justified in making valid conclusions on the basis of our primary end point.
We did not show, as in our previous study, that a bolus of systemic steroid completely reverses bronchodilator subsensitivity after regular treatment with formoterol 24 g bid. 7 Our results suggested only a partial reversal of subsensitivity with both IV hydrocortisone and inhaled budesonide, in that the albuterol responses were no longer significantly different from placebo, but at the same time they were not significantly different from formoterol alone. What are the possible explanations to account for this finding? We used a smaller dose of systemic steroid (hydrocortisone, 200 mg) in the current study, as compared with hydrocortisone, 200 mg, plus prednisolone, 50 mg (combined equivalent dose of hydrocortisone 400 mg) in our previous study. We chose to use the maximum recommended daily dose (1.6 mg) of inhaled budesonide (Astra Draco; Lund, Sweden) as well as a standard recommended dose of hydrocortisone (200 mg) for the treatment of acute asthma. 18 It is conceivable that the acute effects of inhaled and IV corticosteroids on airway ␤ 2 -adrenoceptors may be dose related.
Another factor that may have influenced the results was that in our previous study 7 we had used repeated puffs of formoterol to construct the DRC; consequently, we had evaluated the time profile after the last puff. We did not evaluate the time profile after the last puff in the present study when we used albuterol, because it has a much shorter duration of action. The degree of corticosteroid reversibility may also relate to the intrinsic activity of the agonist in terms of albuterol exhibiting a lower agonist activity compared with formoterol, a full agonist. 18 We had also found no significant increase in Bmax at 1 h after the corticosteroid bolus dose in the previous study, 7 as opposed to evaluating effects at 2 h in the current study. The choice of making measurements 2 h after corticosteroid administration was based on in vitro data showing that dexamethasone increases gene transcription of ␤ 2 -adrenoceptor messenger RNA, with a peak effect occurring within 2 h. 19 Further studies using different corticosteroid doses and time profiles are indicated to further evaluate these effects.
It is also worth comparing the current data with another study in which we observed rapid reversal of formoterol-induced subsensitivity to adenosine monophosphate bronchoprotection and lymphocyte ␤ 2 -adrenoceptor down-regulation, at 2 h after inhalation of a 1,600-g bolus dose of budesonide. 20 This may reflect differential effects of corticosteroids on ␤ 2 -adrenoceptors of airway mast cells compared with smooth muscle. It is known that ␤ 2 -agonist-induced bronchoprotective subsensitivity is more pronounced for effects on mast cells than smooth muscle. 21 The degree of formoterol-induced downregulation of lymphocyte ␤ 2 -adrenoceptors was greater in our previous study, 20 probably reflecting the measurement at 2 h after the last dose of formoterol, in contrast to 24 h in the current study.
It is known that ␤ 2 -adrenoceptor polymorphism at codon 16 determines the propensity for bronchodilator subsensitivity and ␤ 2 -adrenoceptor down-regulation, in particular with the homozygous Gly-16 genotype. 5, 22 In our study, almost all of the patients who were homozygous Gly-16 or heterozygous Gly/ Arg-16 exhibited bronchodilator desensitization. Indeed, the only subject who did not show subsensitivity for FEV 1 response was homozygous for arginine at codon 16 of the ␤ 2 -adrenoceptor. A population-based study has shown that only 11% of subjects have the homozygous Arg-16 genotype, 11 and so the majority of patients who have the Gly-16 allele will be predisposed to down-regulation. We accept the limitations of our study in that we have studied stable, moderate-to-severe asthmatic subjects in a controlled laboratory environment. In an acute exacerbation, there would be increased bronchomotor tone, which might influence the bronchodilator response to albuterol as a consequence of altered airway geometry. 18 Our study had limited power (80%) because of the small sample size. Thus, we are unable to exclude the possibility that a difference between treatments in ⌬FEV 1 response (as AUC) of Ͻ 20% between treatments may have occurred, resulting in a false-negative result. Nevertheless, we were able to show a significant rightward shift in the albuterol dose response comparing placebo and formoterol pretreatment.
In conclusion, bronchodilator subsensitivity to repeated puffs of albuterol developed after regular treatment with formoterol, for effects on FEV 1 and FEF 25-75% response. This desensitization was only partially overcome 2 h after administration of a bolus dose of systemic hydrocortisone or inhaled budesonide. These findings highlight the potential problems associated with the regular use of long-acting ␤ 2 -agonist therapy in asthma. Further studies are required to evaluate the effects of regular treatment with long-acting ␤ 2 -agonists on the albuterol response in the setting of increased bronchomotor tone in acute severe asthma and the influence of acute corticosteroid administration. Such studies should also address acute effects in patients who are particularly susceptible to ␤ 2 -adrenoceptor down-regulation because of genetic polymorphism.
